Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. Co.'s drug candidates include: OV935, which is being developed in a joint collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies; OV101, which is for the treatment of Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders that are characterized by similar symptoms; and OV329 (GABA aminotransferase inhibitor), which is a preclinical compound being developed by Co. for the treatment of seizures associated with Tuberous Sclerosis Complex and Infantile Spasms. The OVID stock yearly return is shown above.
The yearly return on the OVID stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OVID annual return calculation with any dividends reinvested as applicable (on ex-dates).
|